Home > Insider Trading > Filing (0000899243-15-008448)

Filing Details

Accession Number:: 0000899243-15-008448
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-18 19:55:39
Reporting Period:: 2015-08-14

Filing Date:: 2015-11-18
Accepted Time:: 2015-11-18 19:55:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631574	Wave Life Sciences Ltd.	WVE	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657768	Ken Takanashi	C/O Shin Nippon Biomedical Laboratories, 2438 Miyanoura-Machi, Kagoshima City Kagoshima M0 891-1394		Yes	No	Yes	No
1657770	Shin Nippon Biomedical Laboratories, Ltd.	2438 Miyanoura-Machi, Kagoshima City Kagoshima M0 891-1394		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2015-11-16	161,663	$0.00	1,859,130	No	4	C	Indirect	See Footnote
Ordinary Shares	Acquisiton	2015-11-16	125,000	$16.00	1,984,130	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Series B Preferred Shares	Acquisiton	2015-08-14	161,663	$12.37	161,663	$0.00
Ordinary Shares	Series B Preferred Shares	Disposition	2015-11-16	161,663	$0.00	161,663	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
161,663			No	4	P	Indirect
0			No	4	C	Indirect

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Ordinary Shares	Series A Preferred Shares	$0.00			3,901,348	3,901,348	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
	3,901,348	3,901,348	Indirect

Footnotes

Shares held by SNBL USA, Ltd. ("SNBL USA"), an affiliate of Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Ken Takanashi, a director of the Issuer, is a director of SNBL and SNBL USA and each of Mr. Takanashi and SNBL may be deemed to beneficially own the reported securities held by SNBL USA.
The Series B Preferred Shares automatically converted into Ordinary Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of its Ordinary Shares.
Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi and SNBL each disclaim beneficial ownership of the reported securities held by SNBL USA, and Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL, in each case except to the extent of his or its respective pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL or SNBL USA. The filing of this Form 4 shall not be construed as an admission that SNBL is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA.
The reported shares are held as follows; 1,697,467 shares are held by SNBL and 286,663 shares are held by SNBL USA.
The Series A Preferred Shares are convertible into Ordinary Shares on a one-for-one basis at any time at the option of the holder and have no expiration date.
Shares held by SNBL.
Share amounts reflect a 4.0415917-for-1 forward split of the Issuer's shares on November 1, 2015. The securities were purchased for $12.37 per share on a post-split basis.